Personalized prediction for a 41 year old woman who takes Loratadine And Pseudoephedrine Sulfate, Sertraline, Atomoxetine Hydrochloride (an AI-powered real world drug study)

Summary:

This is a personalized prediction of potential side effects and undetected conditions for up to one year, if you would have adverse effects. The study is created by eHealthMe based on data from the FDA.

What are the drugs?

Loratadine and pseudoephedrine sulfate has active ingredients of loratadine; pseudoephedrine sulfate. It is often used in allergies. eHealthMe is studying from 686 Loratadine and pseudoephedrine sulfate users. Check the latest studies of Loratadine and pseudoephedrine sulfate.
Sertraline has active ingredients of sertraline hydrochloride. It is often used in depression. eHealthMe is studying from 153,257 Sertraline users. Check the latest studies of Sertraline.
Atomoxetine hydrochloride has active ingredients of atomoxetine hydrochloride. It is often used in attention deficit hyperactivity disorder. eHealthMe is studying from 991 Atomoxetine hydrochloride users. Check the latest studies of Atomoxetine hydrochloride.

What are the conditions?

Allergies is found to be associated with 4 drugs and 92 conditions by eHealthMe. Check the latest studies of Allergies.
Anxiety is found to be associated with 4,618 drugs and 5,407 conditions by eHealthMe. Check the latest studies of Anxiety.
Add (attention deficit disorder-difficult to define) is found to be associated with 805 drugs and 1,366 conditions by eHealthMe. Check the latest studies of Add.

Potential side effects:

Anaphylaxis

7.83% for females aged 41 (±5) who have allergies

Angioedema

5.53% for females aged 41 (±5) who have allergies

Cough

5.07% for females aged 41 (±5) who have allergies

Depression

6.95% for females aged 41 (±5) who have allergies and anxiety
6.9% for females aged 41 (±5) who have add and anxiety
5.97% for females aged 41 (±5) who have allergies and add

Diarrhea

6.15% for females aged 41 (±5) who have allergies and anxiety
5.77% for females aged 41 (±5) who have add and anxiety

Disturbance in attention

7.71% for females aged 41 (±5) who have allergies and add

Dizziness

8.78% for females aged 41 (±5) who have allergies and anxiety
8.46% for females aged 41 (±5) who have add and anxiety
6.21% for females aged 41 (±5) who have allergies and add

Drowsiness

6.87% for females aged 41 (±5) who have allergies and add

Drug hypersensitivity

5.53% for females aged 41 (±5) who have allergies

Drug ineffective

19.43% for females aged 41 (±5) who have allergies and add
10.68% for females aged 41 (±5) who have add and anxiety
8.53% for females aged 41 (±5) who have allergies and anxiety
6.16% for females aged 41 (±5) who take atomoxetine hydrochloride
6.16% for females aged 41 (±5) who take loratadine and pseudoephedrine sulfate
6.16% for females aged 41 (±5) who take sertraline

Dyspnea

5.26% for females aged 41 (±5) who have allergies and anxiety

Fatigue

12.82% for females aged 41 (±5) who have allergies and add
10.64% for females aged 41 (±5) who have add and anxiety
10.09% for females aged 41 (±5) who have allergies and anxiety
6.53% for females aged 41 (±5) who take loratadine and pseudoephedrine sulfate
6.53% for females aged 41 (±5) who take sertraline
6.53% for females aged 41 (±5) who take atomoxetine hydrochloride

Febrile neutropenia

5.07% for females aged 41 (±5) who have allergies

Feeling abnormal

8.87% for females aged 41 (±5) who have allergies and add
5.94% for females aged 41 (±5) who have add and anxiety
5.24% for females aged 41 (±5) who have allergies and anxiety

Fever

5.07% for females aged 41 (±5) who have allergies

Headache

12.44% for females aged 41 (±5) who have allergies and add
10.07% for females aged 41 (±5) who have add and anxiety
9.29% for females aged 41 (±5) who have allergies and anxiety
5.92% for females aged 41 (±5) who take atomoxetine hydrochloride
5.92% for females aged 41 (±5) who take loratadine and pseudoephedrine sulfate
5.92% for females aged 41 (±5) who take sertraline

Hypersensitivity

9.22% for females aged 41 (±5) who have allergies

Insomnia

7.21% for females aged 41 (±5) who have allergies and anxiety
7.09% for females aged 41 (±5) who have add and anxiety
6.0% for females aged 41 (±5) who have allergies and add

Itching

5.07% for females aged 41 (±5) who have allergies

Malaise

5.87% for females aged 41 (±5) who have allergies and anxiety
5.48% for females aged 41 (±5) who have add and anxiety

Nausea

10.77% for females aged 41 (±5) who have add and anxiety
10.71% for females aged 41 (±5) who have allergies and anxiety
10.21% for females aged 41 (±5) who have allergies and add
6.51% for females aged 41 (±5) who take loratadine and pseudoephedrine sulfate
6.51% for females aged 41 (±5) who take sertraline
6.51% for females aged 41 (±5) who take atomoxetine hydrochloride

Nausea and vomiting

5.7% for females aged 41 (±5) who have allergies and anxiety
5.34% for females aged 41 (±5) who have add and anxiety

Pain

8.55% for females aged 41 (±5) who have allergies and anxiety
7.85% for females aged 41 (±5) who have add and anxiety

Rashes

13.36% for females aged 41 (±5) who have allergies

Stress and anxiety

13.17% for females aged 41 (±5) who have allergies and anxiety
12.85% for females aged 41 (±5) who have add and anxiety
9.69% for females aged 41 (±5) who have allergies and add

Urticaria

5.53% for females aged 41 (±5) who have allergies

Weakness

5.4% for females aged 41 (±5) who have allergies and anxiety
5.07% for females aged 41 (±5) who have add and anxiety

Weight increased

5.31% for females aged 41 (±5) who have allergies and anxiety

Potential co-existing conditions:

Asthma

5.99% for females aged 41 (±5) who have allergies

Bipolar disorder

5.6% for females aged 41 (±5) who have allergies and anxiety
5.19% for females aged 41 (±5) who have add and anxiety

Breast cancer

11.52% for females aged 41 (±5) who have allergies

Constipation

7.37% for females aged 41 (±5) who have allergies

Crohn's disease

5.15% for females aged 41 (±5) who have allergies and anxiety

Gastroesophageal reflux disease

8.7% for females aged 41 (±5) who have allergies and anxiety
7.76% for females aged 41 (±5) who have add and anxiety

High blood pressure

8.89% for females aged 41 (±5) who have allergies and anxiety
7.82% for females aged 41 (±5) who have add and anxiety

Insomnia

11.1% for females aged 41 (±5) who have allergies and anxiety
9.68% for females aged 41 (±5) who have add and anxiety

Migraine

6.02% for females aged 41 (±5) who have allergies and anxiety
5.47% for females aged 41 (±5) who have add and anxiety

Multiple sclerosis

9.61% for females aged 41 (±5) who take loratadine and pseudoephedrine sulfate
9.61% for females aged 41 (±5) who take sertraline
9.61% for females aged 41 (±5) who take atomoxetine hydrochloride

Nausea

5.94% for females aged 41 (±5) who have allergies and anxiety
5.15% for females aged 41 (±5) who have add and anxiety

Neoplasm malignant

8.29% for females aged 41 (±5) who have allergies

Pain

16.37% for females aged 41 (±5) who have allergies and anxiety
14.4% for females aged 41 (±5) who have add and anxiety

Rheumatoid arthritis

6.84% for females aged 41 (±5) who take loratadine and pseudoephedrine sulfate
6.84% for females aged 41 (±5) who take sertraline
6.84% for females aged 41 (±5) who take atomoxetine hydrochloride
5.17% for females aged 41 (±5) who have allergies and anxiety

Sleep disorder

7.01% for females aged 41 (±5) who have allergies and anxiety
6.21% for females aged 41 (±5) who have add and anxiety

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

How the study uses the data?

The study is based on gender, age, active ingredients of any drugs used, and more. Other drugs that have the same active ingredients (e.g. generic drugs) are considered.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

Related publications that referenced our studies

Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
Izgi C, Erdem G, Mansuroglu D, Kurtoglu N, Kara M, Gunesdogdu F, "Severe hypokalemia probably associated with sertraline use", Annals of Pharmacotherapy, 2014 Jan .
Lufi D, Bucherman M, Akita M, Cohen R, Sibani C, "The effect of methylphenidate on speech patterns of children with attention deficit disorder", Journal of Behavioral Health, 2012 Jan .

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.